维奈克拉联合CLIA强化化疗治疗新诊断急性髓系白血病或高危骨髓增生异常综合征:单中心单臂2期试验队列
该单中心单臂2期试验纳入50例18-65岁新诊断急性髓系白血病、混合表型急性白血病或高危骨髓增生异常综合征患者,接受维奈克拉联合CLIA方案(克拉屈滨、大剂量阿糖胞苷、去甲氧柔红霉素)治疗。复合完全缓解率达94%,82%患者可测量残留病阴性,12个月总生存率85%,安全性可控。
要点
- 维奈克拉联合CLIA方案在年轻患者中复合完全缓解率达94%。
- 82%患者达到可测量残留病阴性,12个月总生存率85%。
- 常见3级及以上不良事件为发热性中性粒细胞减少(84%)。
核心结论
- 维奈克拉联合CLIA方案在新诊断急性髓系白血病或高危骨髓增生异常综合征患者中安全有效,产生高比例持久MRD阴性缓解。
研究设计与样本
- 单中心、单臂、2期CLIA试验的独立队列,在美国MD Anderson癌症中心进行。
- 纳入50例18-65岁新诊断急性髓系白血病、混合表型急性白血病或高危骨髓增生异常综合征患者。
- 患者接受克拉屈滨、阿糖胞苷、去甲氧柔红霉素联合维奈克拉治疗。
主要发现
- 47例(94% [95% CI 83-98])患者达到复合完全缓解,总体缓解率相同。
- 45例可评估患者中37例(82% [95% CI 68-92])可测量残留病阴性。
- 12个月时估计缓解持续时间74% (95% CI 60-92),无事件生存期68% (54-85),总生存期85% (75-97)。
- 最常见3级及以上不良事件为发热性中性粒细胞减少(42例[84%])、感染(6例[12%])和丙氨酸氨基转移酶升高(6例[12%])。
关键数值与推荐
- 维奈克拉400 mg在第2-8天给予,每个疗程。
- 已知FLT3-ITD或FLT3-TKD突变患者接受米哚妥林或吉瑞替尼。
临床怎么用
- 对于65岁及以下新诊断急性髓系白血病或高危骨髓增生异常综合征患者,可考虑维奈克拉联合CLIA强化化疗方案。
- 治疗期间需密切监测发热性中性粒细胞减少和感染,尤其FLT3突变患者接受联合FLT3抑制剂时。
局限性
- 未设对照组,结果需进一步随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Addition of the BCL2 inhibitor venetoclax to lower intensity therapy has been shown to improve overall survival in older (aged 75 years or older) and unfit patients with newly diagnosed acute myeloid leukaemia. The aim of this study was to investigate the activity of venetoclax combined with intensive chemotherapy in patients aged 65 years or younger with acute myeloid leukaemia. METHODS: This cohort study was done at the MD Anderson Cancer Center in the USA, as part of the single-centre, single arm, phase 2, CLIA trial. Here we report on the independent cohort investigating the safety and activity of venetoclax added to intensive chemotherapy (the CLIA regimen [cladribine, high-dose cytarabine, idarubicin]). Eligible patients were aged 18-65 years with a new diagnosis of acute myeloid leukaemia, mixed phenotype acute leukaemia, or high-risk myelodysplastic syndrome (≥10% blasts or International Prognostic Scoring System ≥2 [intermediate]), who received no previous potentially curative therapy for leukaemia. Patients received cladribine (5 mg/m2) and cytarabine (1·5 g/m2 for patients aged <60 years, 1 g/m2 for patients aged ≥60 years) intravenously on days 1-5 and idarubicin (10 mg/m2) intravenously on days 1-3. Consolidation was cladribine (5 mg/m2) and cytarabine (1 g/m2 for patients aged <60 years and 0·75 g/m2 for patients aged ≥60 years) on days 1-3 and idarubicin (8 mg/m2) on days 1-2. Venetoclax (400 mg) was given on days 2-8 with each course. Patients with a known FLT3-ITD or FLT3-TKD mutation received midostaurin or gilteritinib. The primary outcome was composite complete response (complete response plus complete response with incomplete blood count recovery). Secondary outcomes were overall response, duration of response, event-free survival, overall survival, and safety. This trial was registered with ClinicalTrials.gov, NCT02115295. FINDINGS: Between Feb 25, 2019, and March 23, 2021, 77 patients were assessed for eligibility, 50 of whom were enrolled. Median age was 48 years (IQR 37-56). 47 (94% [95% CI 83-98]) patients had composite complete response, with the same proportion also having an overall response; two (4% [1-14]) patients did not respond, and one (2% [0-11]) patient died during induction. 37 (82% [95% CI 68-92]) of 45 patients had undetectable measurable residual disease (MRD). At a median follow-up of 13·5 months (IQR 6·4-19·5), the median duration of response, event-free survival, and overall survival were not reached. At 12 months, the estimated duration of response was 74% (95% CI 60-92), event-free survival was 68% (54-85), and overall survival was 85% (75-97). The most common adverse events of grade 3 or worse were febrile neutropenia (42 [84%] patients), infection (six [12%]), and alanine aminotransferase elevations (six [12%]). There was one death during induction in a patient treated with CLIA-venetoclax plus a FLT3 inhibitor. Two patients died of infectious complications while in complete response in consolidation cycles, both of whom had FLT3-mutated acute myeloid leukaemia and were receiving combined therapy with a FLT3 inhibitor. No deaths were deemed to be treatment related. INTERPRETATION: Venetoclax added to CLIA was safe and active in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome, producing high rates of durable MRD-negative remissions and encouraging event-free survival and overall survival. FUNDING: MD Anderson Cancer Center.
引用
- Kadia TM, Reville PK, Borthakur G, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021. PMID: 34329576. doi:10.1016/S2352-3026(21)00192-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。